Optical Genome Mapping Market (2026-2036)

The growth of this market is mainly driven by the ability of optical genome mapping to detect all classes of structural variants across the whole genome in a single assay, the increasing adoption of OGM as an alternative to karyotyping, FISH, and chromosomal microarray in hematologic malignancies and constitutional genetic disorders, the publication of expert recommendations supporting its clinical use, and improving reimbursement for OGM-based testing. In addition, the growing use of OGM in reproductive health and prenatal research, cell and gene therapy and cell line quality control, and genome assembly, together with the introduction of higher-throughput systems and AI-enabled analysis software, is further supporting the growth of this market.

The Optical Genome Mapping Market, also referred to as the OGM market, genome mapping market, or high-resolution structural variant mapping market, comprises the instruments, consumables, software, and services used to image and analyze ultra-long, labeled DNA molecules in order to detect structural variants across the entire genome. The market includes OGM systems that linearize and image DNA molecules hundreds of kilobases long in nanochannel arrays; consumables such as nanochannel array flowcells and DNA isolation and labeling kits; analysis and interpretation software; and research and clinical testing services, including laboratory-developed tests for hematologic malignancies and constitutional genetic disorders. It also includes electronic genome mapping, which detects labeled ultra-long DNA molecules electronically in nanochannels. These technologies enable the detection of balanced and unbalanced structural variants, including translocations, inversions, insertions, deletions, duplications, and copy number variants, at much higher resolution than traditional cytogenetic methods. The market ecosystem extends from reagent and component suppliers to platform manufacturers, software providers, clinical and research laboratories, pharmaceutical and cell and gene therapy companies, and payers.

The market is experiencing strong growth as clinical laboratories seek to replace or consolidate traditional cytogenetic methods, which require multiple separate tests and offer limited resolution. Karyotyping detects only large chromosomal changes and depends on cell culture and expert interpretation, FISH examines only a small number of predefined loci, and chromosomal microarray cannot detect balanced rearrangements. Optical genome mapping can detect all of these variant classes in a single genome-wide assay, reducing the number of tests, turnaround time, and the risk of missed findings. In a T-cell acute lymphoblastic leukemia study highlighted by Bionano in Q2 2026, OGM detected abnormalities in 97.8% of cases, compared with 55% for karyotyping, illustrating the diagnostic yield advantage that is driving clinical adoption.

The leading platform provider reflects the shift toward clinical use. Bionano Genomics, the leading provider of optical genome mapping (OGM) systems, reported 2025 revenue of USD 28.5 million, with consumables and software revenue up 7%, 30,171 nanochannel array flowcells sold, and an installed base of 387 OGM systems at the end of 2025, including 32 new installations. In Q2 2026, Bionano reported revenue of USD 8.2 million, up 21% year over year, with consumables revenue up 31% to USD 4.3 million and 9,219 flowcells sold, up 27%, driven by increased clinical adoption and higher utilization at existing and new clinical sites, and raised the low end of its 2026 revenue guidance to USD 31 million to USD 33 million. The growth in consumables and flowcell volumes, despite a decline in instrument revenue to USD 6.4 million in 2025 from USD 8.0 million in 2024, indicates that market growth is increasingly driven by utilization of the installed base in clinical settings rather than by new capital purchases.

Clinical guidelines and reimbursement are providing important support for adoption. In May 2025, the International Consortium for Optical Genome Mapping (ICOGM) published expert recommendations in the American Journal of Hematology, developed by 19 experts, recommending OGM as a first-line test for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), B-cell and T-cell acute lymphoblastic leukemia, and pediatric leukemias, in place of karyotyping and fluorescence in situ hybridization (FISH), when high-resolution genome-wide structural variant detection is needed. The recommendations also position OGM as an alternative to traditional methods in chronic lymphocytic leukemia, plasma cell neoplasms and multiple myeloma, aplastic anemia, bone marrow failure syndromes, and germline predisposition syndromes when conventional methods fail or are inconclusive. Under the final 2026 Clinical Laboratory Fee Schedule, the U.S. Centers for Medicare & Medicaid Services (CMS) increased the payment rate for Category I CPT code 81195, which covers the use of OGM for genome-wide cytogenomic analysis of hematologic malignancies, by 47% to USD 1,853.22 from USD 1,263.53, effective January 1, 2026. A second Category I code, CPT 81354, covers the use of OGM in constitutional genetic disease, providing a reimbursement pathway for postnatal genetic testing.

Applications are expanding beyond hematologic malignancies. Research is increasingly evaluating OGM in reproductive health and prenatal testing, with Bionano reporting that thirteen 2026 reproductive health and prenatal studies covering 730 subjects had been published by Q2 2026, as well as in solid tumors, multiple myeloma, rare disease, and cell and gene therapy, where OGM is used to assess genome integrity and off-target structural changes in engineered cell lines and edited cells. Bionano reported 136 peer-reviewed publications in Q4 2025 alone, reflecting the growing body of evidence across these applications.

The competitive landscape is also evolving. Nabsys, which develops electronic genome mapping technology, works with Hitachi High-Tech America through the RAMP UP program to place its OhmX platform in leading research laboratories, and in May 2026 announced multiple OhmX installations at Columbia University for structural variant analysis in AML and MDS. Nabsys and Hitachi also presented electronic genome mapping data at the Japanese Society of Human Genetics annual meeting in December 2025, including high-resolution detection of TP53 deletions. In China, Beijing Genome Precision Technology, an OEM partner of Bionano, received NMPA Class I registrations for DNA labeling and bone marrow aspirate DNA isolation kits for in vitro diagnostic use in hematologic malignancies, supporting clinical use of OGM in the country.

At the same time, the market faces competition from sequencing-based approaches. Long-read sequencing and mapped-read technologies can also detect structural variants, and laboratories are evaluating the relative cost, resolution, and workflow advantages of OGM against these alternatives. As a result, the ability to demonstrate clinical utility, cost-effectiveness, and workflow simplicity, supported by higher-throughput systems and AI-enabled software, is expected to be critical for market growth over the forecast period.